RecruitingNCT06557057

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Sponsor

Mayo Clinic

Enrollment

66 participants

Start Date

Nov 16, 2023

Study Type

OBSERVATIONAL

Conditions

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

Sex: FEMALE

Post-menopausal women with hormone receptor positive breast cancer, ductal carcinoma in situ (DCIS), or with other high risk breast conditions. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy.
women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center.
women who will be starting Tamoxifen (comparative group)
healthy post menopausal women will also be recruited.

Established diagnosis of diabetes
Therapy with medications that could affect glucose metabolism
Screening fasting glucose ≥ 126 mg/dl, and/or HbA1c ≥ 6.5%
History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication